-$0.08 EPS Expected for Acasti Pharma Inc. (NASDAQ:ACST) This Quarter

Brokerages expect that Acasti Pharma Inc. (NASDAQ:ACST) will post earnings per share (EPS) of ($0.08) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Acasti Pharma’s earnings. Acasti Pharma reported earnings per share of ($0.16) in the same quarter last year, which indicates a positive year-over-year growth rate of 50%. The company is expected to issue its next earnings report on Tuesday, February 8th.

On average, analysts expect that Acasti Pharma will report full-year earnings of ($0.11) per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will report earnings of ($0.27) per share. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Acasti Pharma.

Acasti Pharma (NASDAQ:ACST) last announced its quarterly earnings results on Wednesday, November 10th. The biopharmaceutical company reported $0.03 EPS for the quarter.

Separately, Oppenheimer assumed coverage on Acasti Pharma in a research note on Tuesday, December 21st. They set an “outperform” rating and a $6.00 price target for the company.

Several hedge funds have recently bought and sold shares of ACST. Renaissance Technologies LLC acquired a new stake in shares of Acasti Pharma in the second quarter valued at about $979,000. Morgan Stanley grew its stake in shares of Acasti Pharma by 885.6% in the first quarter. Morgan Stanley now owns 378,808 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 340,372 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Acasti Pharma during the 2nd quarter valued at approximately $62,000. Squarepoint Ops LLC grew its stake in Acasti Pharma by 392.4% during the 2nd quarter. Squarepoint Ops LLC now owns 94,500 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 75,309 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Acasti Pharma during the 3rd quarter valued at approximately $38,000. Institutional investors and hedge funds own 0.75% of the company’s stock.

NASDAQ:ACST traded up $0.06 on Friday, hitting $1.39. 699,579 shares of the stock were exchanged, compared to its average volume of 1,099,499. The stock has a market cap of $36.21 million, a PE ratio of -2.96 and a beta of 1.79. The stock has a fifty day moving average of $1.35 and a 200-day moving average of $2.38. Acasti Pharma has a fifty-two week low of $1.04 and a fifty-two week high of $9.76.

About Acasti Pharma

Acasti Pharma Inc, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia.

See Also: What is a balanced fund?

Get a free copy of the Zacks research report on Acasti Pharma (ACST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acasti Pharma (NASDAQ:ACST)

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.